Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders
| Autor: | Carlos Tostes Guerreiro, Amilton Antunes Barreira, Marlise de Castro Ribeiro, Rinaldo Claudino, Alessandro Finkelsztejn, Monica Fiuza Koncke Parolin, Tarso Adoni, Simone Scherpenhuijzen, Yara Dadalti Fragoso, Taysa Alexandrino Gonsalves Jube Ribeiro, André Palma da Cunha Matta, Daniel Lima Varela, Henry Sato, Thereza Cristina A Winckler, Fabio Siquineli, Nise Alessandra de Carvalho Sousa, Paulo Diniz da Gama, Vanessa Daccach Marques, Carlos Bernardo Tauil, Juliana Finkelsztejn, Rogerio Rizo Morales, Marcus Goncalves, Samira Luisa Apostolos-Pereira, Heloisa Helena Ruocco, Eber Castro Correa, Joseph Bruno Bidin Brooks, Maria Lucia Brito Ferreira, Soniza Vieira Alves-Leon |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Multiple Sclerosis Physical Therapy Sports Therapy and Rehabilitation MARCHA (LOCOMOÇÃO) Life Change Events 03 medical and health sciences 0302 clinical medicine Physical medicine and rehabilitation Potassium Channel Blockers medicine Humans Gait disorders In patient Prospective Studies 030212 general & internal medicine 4-Aminopyridine Adverse effect Prospective cohort study Gait Disorders Neurologic Aged business.industry Multiple sclerosis Rehabilitation Middle Aged medicine.disease Gait Preferred walking speed Female Observational study Neurology (clinical) business 030217 neurology & neurosurgery |
| Zdroj: | Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP |
| Popis: | Background Fampridine is a broad-spectrum voltage-dependent potassium channel blocker that enhances synaptic transmission. The drug has been shown to be able to ameliorate conduction in demyelinated axons, thereby leading to improved gait in patients with multiple sclerosis (MS). Objective To assess the "real-life" efficacy and safety of fampridine prescribed for gait disorders in MS. This was an observational and prospective study carried out at MS Units participating in the Brazilian Multiple Sclerosis Study Group. Methods Patients with MS and gait disorders were prescribed fampridine (10 mg twice a day), irrespectively of the degree of disability determined by MS. Neurological disability determined by MS was assessed with the expanded disability scale score (EDSS). Outcomes for efficacy and safety of the drug were evaluated by the 25 foot-walk test and by the adverse events of fampridine. Results The time taken to walk 25 feet decreased by 20% or more in 62 patients (70%). Twenty-five patients were considered to be non-responders to this treatment. Improvement in walking speed was independent of improvement of disability. Mild or moderate adverse events were reported in 8% of patients. Conclusion Fampridine is an efficient and safe therapeutic option for patients with MS and gait disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|